Skip to main content
. Author manuscript; available in PMC: 2020 Aug 31.
Published in final edited form as: Epigenomics. 2012 Oct;4(5):571–589. doi: 10.2217/epi.12.52

Figure 2. Romidepsin synergistically interacts with bortezomib to induce apoptosis in human myeloma cells.

Figure 2.

(A) Human myeloma U266 and RPMI 8226 cells were exposed (48 h) to 2–3 nM FK228 in the absence or presence of 3–4 nM Btzmb (Valcade), after which the percentage of Annexin V+ (apoptotic) cells were determined by flow cytometry. (B) Primary CD138+ multiple myeloma cells were isolated from bone marrow sample of an patient with multiple myeloma. CD138+ and CD138- cells were then treated for 24 h with 3 nM FK228 ± 3 nM Btzmb, after which apoptosis were assessed by Annexin V-FITC staining and flow cytometry.

Btzmb: Bortezomib; Ctrl: Control; FK228: Romidepsin; MM: Multiple myeloma.

[Grant S, Dai Y, Unpublished data].